Current anticoagulant drugs also trigger excessive bleeding, but a new humanized antibody that blocks the enzyme factor XII can prevent thrombosis without this adverse effect (Larsson M et al. Sci Transl Med. 2014;6:222ra17).
Previous research showed that factor XII, which is essential for clot formation, influences thrombosis risk but not bleeding. Scientists have developed factor XII inhibitors, but those have off-target effects that compromise their safety in patients.
Hampton T. Experimental Anticoagulant Free of Bleeding Risk. JAMA. 2014;311(13):1282. doi:10.1001/jama.2014.2892